{"id":516,"date":"2017-04-18T19:32:16","date_gmt":"2017-04-18T10:32:16","guid":{"rendered":"https:\/\/bionauts.jp\/?page_id=516"},"modified":"2017-04-18T19:32:16","modified_gmt":"2017-04-18T10:32:16","slug":"therapeutic-compound-for-sarcopenia-2","status":"publish","type":"page","link":"https:\/\/bionauts.jp\/?page_id=516","title":{"rendered":"Therapeutic compound for Sarcopenia"},"content":{"rendered":"<h3><strong>Core Benefit<\/strong><\/h3>\n<ul>\n<li><strong>Novel and multifaceted therapeutic strategy with the TAZ activator for muscle-wasting disorders.<\/strong><\/li>\n<\/ul>\n<h3><strong>Background and Technology<\/strong><\/h3>\n<p>The transcriptional coactivator with a PDZ-binding motif (TAZ) cooperates with various transcriptional factors and plays various roles. Dr. Hata and colleagues developed a cell-based assay to screen 18,458 chemical compounds for TAZ activators. Finally, they focused on one compound, IBS008738, which increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin<em>\u00a0in vitro<\/em>. IBS008738 facilitates muscle repair in cardiotoxin-induced muscle injury and prevents dexamethasone-induced muscle atrophy\u00a0<em>in vivo<\/em>. These findings also support the idea that TAZ is a potential therapeutic target for muscle atrophy.<\/p>\n<h3><strong>Data<\/strong><\/h3>\n<p><a href=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-large wp-image-397\" src=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1-1024x389.png\" alt=\"%e7%84%a1%e9%a1%8c\" width=\"840\" height=\"319\" srcset=\"https:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1-1024x389.png 1024w, https:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1-300x114.png 300w, https:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1-768x292.png 768w, https:\/\/bionauts.jp\/wp-content\/uploads\/2016\/12\/0d40a5e4a645fc6b96e767d64ac0878e-1.png 1043w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<ul>\n<li>(A) IBS008738facilitates the repair of cardiotoxin-injected muscles\u00a0<em>in vivo<\/em>via promotion of satellite stem cell replication and differentiation into skeletal muscle lineage.<\/li>\n<li>(B) IBS008738 prevents dexamethasone-induced muscle atrophy\u00a0<em>in vivo<\/em>by upregulation of protein synthesis and suppression of muscle-specific E3 ligases.<\/li>\n<li>IBS008738 competes with myostatin that inhibits muscle growth and differentiation.<\/li>\n<li>The malignant transformation of cancer cells with IBS008738 was not confirmed.<\/li>\n<\/ul>\n<h3><strong>Publication and Patent<\/strong><\/h3>\n<p><span style=\"color: #ff0000;\">If you want these public information, please contact us!<\/span><\/p>\n<h3><strong>Expectations<\/strong><\/h3>\n<p>We are looking for a pharmaceutical company to collaborate with the researchers and develop this compound further under the patent licensing. IBS008738 and other TAZ activator could be provided for evaluation by MTA.<\/p>\n<p>Product No. TP0411<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Core Benefit Novel and multifaceted therapeutic strategy with the TAZ activator for muscle-wasting disorders.  &hellip; <a href=\"https:\/\/bionauts.jp\/?page_id=516\" class=\"more-link\"><span class=\"screen-reader-text\">&#8220;Therapeutic compound for Sarcopenia&#8221; \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/pages\/516"}],"collection":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=516"}],"version-history":[{"count":1,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/pages\/516\/revisions"}],"predecessor-version":[{"id":517,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/pages\/516\/revisions\/517"}],"wp:attachment":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}